Topic Dossier

Economy

Grifols Plans Up to $5 Billion IPO of US Unit

First article: 25 mar. 2026, 13:52 | Last update: 25 mar. 2026, 13:52 | 1 source | 1 article
#ipo#grifols#pharma#usmarket

Multiple sources. Less manipulation.

Editorial Analysis

Based on 1 source, 1 article

Grifols, a Barcelona-based pharmaceutical company specializing in plasma-derived therapies, is preparing to launch an IPO for its US unit, potentially raising up to $5 billion. The company intends to use the funds to pay down debt and streamline its operations, focusing on its core business of plasma collection and fractionation. This strategic move reflects Grifols' efforts to improve its financial position amid challenging market conditions and increased competition.

Articles about this topic

Grifols Aims to Raise Up to $5 Billion in IPO of US Unit Foto: Bloomberg
Bloomberg Clara Hernanz Lizarraga 25 mar. 2026, 13:52 (4 hours ago)

Grifols Aims to Raise Up to $5 Billion in IPO of US Unit

Grifols SA aims to raise as much as $5 billion in a potential US listing of its Los Angeles-based biopharma unit, an amount that would value the business at close to four times the size of its parent company, according to a person familiar with the matter.

Read on Bloomberg →